Genprex Announces the Opening for Enrollment of its Phase I/II Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda^® to Treat Non-Small Cell Lung Cancer

Genprex, Inc. announced the opening for patient enrollment of its Acclaim-2 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Keytruda® in patients with late-stage non-small cell lung cancer whose disease progressed after treatment with Keytruda.